Anastrozole is named as an intervention in 27 current clinical trials in our USA, China, UK, India and Ireland registers. 11 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Eli Lilly and Company (7). The most-studied condition is Breast Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 10 |
| Metastatic Breast Cancer | 4 |
| Breast Neoplasms | 3 |
| Breast Cancer, Early Breast Cancer | 2 |
| ER-Positive HER2-Negative Breast Cancer | 2 |
| Advanced Breast Cancer | 2 |
| Breast Ductal Carcinoma In Situ | 1 |
| Invasive Breast Carcinoma | 1 |
| Multicentric Breast Carcinoma | 1 |
| Multifocal Breast Carcinoma | 1 |
| Neoplasm Metastasis | 1 |
| ER-positive Breast Cancer | 1 |
| HER2-negative Breast Cancer | 1 |
| Stage IIB Breast Cancer | 1 |
| Stage III Breast Cancer | 1 |
| Breast Adenocarcinoma | 1 |
| Hormone Receptor Positive | 1 |
| Stage IA Breast Cancer AJCC v7 | 1 |
| Stage IB Breast Cancer AJCC v7 | 1 |
| Low Grade Serous Ovarian Cancer | 1 |
| Solid Tumors, Adult | 1 |
| ER Positive Breast Cancer | 1 |
| Non Small Cell Lung Cancer | 1 |
| HR+/HER2- Advanced/Metastatic Breast Cancer | 1 |
| HR Positive HER2 Negative Advanced Breast Cancer | 1 |
| Locally Advanced Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 7 |
| AstraZeneca | 6 |
| National Cancer Institute (NCI) | 2 |
| Tolmar Inc. | 2 |
| Shandong Suncadia Medicine Co., Ltd. | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Verastem, Inc. | 1 |
| Stemline Therapeutics, Inc. | 1 |
| Olema Pharmaceuticals, Inc. | 1 |
| Novartis Pharmaceuticals | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 |
| Fudan University | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 18 | 6 |
| Clinical trials in China | 14 | 8 |
| Clinical trials in UK | 11 | 5 |
| Clinical trials in India | 9 | 2 |
| Clinical trials in Ireland | 8 | 4 |
A trial with sites in more than one country appears in each of those registers.
27 current trials in our USA, China, UK, India and Ireland registers name Anastrozole as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 11 of the 27 trials are recruiting: 6 with sites in USA, 8 with sites in China, 5 with sites in UK, 2 with sites in India and 4 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Eli Lilly and Company (7), AstraZeneca (6), National Cancer Institute (NCI) (2) and Tolmar Inc (2), among 13 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anastrozole works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anastrozole works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anastrozole (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.